27.28

1.27% -0.35

Gh Research Plc (GHRS)

Overview News Price History Option Chain Discussions Forecast

Gh Research Plc stock is traded at $27.28, with a volume of 163.86K. It is down -1.27% in the last 24 hours and up +10.89% over the past month. GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Previous Close:

$27.63

Open:

$27.62

24h Volume:

163.86K

Relative Volume:

0.63

Market Cap:

$1.87B

Revenue:

Net Income/Loss:

$-48.26M

P/E Ratio:

-34.54

EPS:

-0.7899

Net Cash Flow:

$-45.04M

1W Performance:

-4.98%

1M Performance:

+10.89%

6M Performance:

+63.06%

1Y Performance:

+88.27%

1-Day Range:

$26.75

$28.10

1-Week Range:

$26.75

$29.22

52-Week Range:

$11.32

$31.00

Gh Research Plc Stock (GHRS) Company Profile

Name

Gh Research Plc

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

GHRS's Discussions on Twitter

Compare GHRS vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
GHRS Gh Research Plc	27.28	1.87B	0	-48.26M	-45.04M	-0.7899
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Gh Research Plc Stock (GHRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-13-25	Initiated	Needham	Buy
Jun-04-25	Resumed	Cantor Fitzgerald	Overweight
Mar-13-25	Initiated	Guggenheim	Buy
Mar-07-25	Initiated	RBC Capital Mkts	Outperform
Feb-13-25	Initiated	Cantor Fitzgerald	Overweight
Aug-16-22	Initiated	H.C. Wainwright	Buy
Jun-16-22	Initiated	ROTH Capital	Buy

View All

Gh Research Plc Stock (GHRS) Latest News

Jul 22, 2026

GHRS: GH Research PLC Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Jul 22, 2026

Jul 21, 2026

A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening - marketscreener.com

Jul 21, 2026

GH Research PLC (1KA.DU) Analyst insights, Price targets and Recommendations - Yahoo Finance UK

Jul 21, 2026

Jul 20, 2026

Eli Lilly Drops $3.8 Billion on AtaiBeckley, Sending Psychedelic Stocks Soaring - finance.biggo.com

Jul 17, 2026

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time - mx.advfn.com

Jul 17, 2026

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Sahm

Jul 17, 2026

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer - Sahm

Jul 17, 2026

On Holding Stock And 2 Founder Led Picks Investors Are Watching Closely - Sahm

Jul 17, 2026

Jul 16, 2026

GHR Research PLC stock hits 52-week high at $30.20 - Investing.com

Jul 16, 2026

GHR Research PLC stock hits 52-week high at $30.20 By Investing.com - Investing.com South Africa

Jul 16, 2026

GH Research : GHRS - 24/7 Wall St.

Jul 16, 2026

Why Is GH Research Stock Trading Higher on Thursday? - Benzinga

Jul 16, 2026

Why is GH Research stock surging today? By Investing.com - Investing.com Nigeria

Jul 16, 2026